Horizon Pharma Sees Mid-2019 BLA For Tepro After Solid Phase III TED Data

 
• By Sten Stovall

Horizon Pharma is on track to file its top pipeline asset for regulatory approval this year after its Phase III confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease met primary and secondary endpoints.

Eye
OPTIC Phase III Study Was In thyroid eye disease (TED) • Source: Shutterstock

More from Sensory

More from Therapy Areas